Physician profile
William G Smith
NPI 1730366519
$1,968.22
in general payments reported to CMS, 2019-2025
11 companies · $99.23 in 2025
The $99.23 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $251 · 2021: $424 · 2022: $511 · 2023: $197 · 2024: $20.08 · 2025: $99.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $791.08 | 2019-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $337.25 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $204.65 | 2020-2021 | |
| Abbott Laboratories | $124.08 | 2021-2023 | Freestyle Libre 3 |
| Valeritas, INC. | $123.21 | 2019 | |
| Lilly USA, LLC | $110.94 | 2022-2025 | Zepbound |
| Amgen INC. | $109.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.43 | 2023 | Jardiance |
| Mannkind Corporation | $58.71 | 2022 | |
| Zealand Pharma US, INC. | $17.05 | 2020 | |
| Cequr Corporation | $5.12 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.